Gene therapy with AAV-hOTOF for autosomal recessive deafness
09-10, 08:00– (Europe/Istanbul), Otology 3

Session Chair Session Chair
Speaker Speaker

Graduated in Medicine and Surgery from the University of Navarra in 1980, Doctor of

Medicine and Surgery from the University of Navarra and Specialty in Otorhinolaryngology in

the Department of Otorhinolaryngology of the University Clinic of Navarra, 1982-1985. Doctor

Honoris Causa. Issued by the University of San Pablo de Tucumán, Argentina, March, 2014

Clinical Consultant of the Department of Otorhinolaryngology of the University Clinic of

Navarra since 1992 and Director of the Cochlear Implants program of the University of

Navarra since 1989.

Director of the Department of Otorhinolaryngology of the University Clinic of Navarra since

June 2015.

He is Professor of Otorhinolaryngology at the Faculty of Medicine of the University of

Navarra.

The research activity has been carried out in the general area of Otology-Otoneurology, and he

is Coordinator of the Bioengineering Center of the University of Navarra.

He has more than 100 articles published in national and international journals, 60 book

chapters, monographs and 9 books.

He has participated in more than 900 conferences, round tables, national and international

instruction courses.

He is a member of different scientific societies and editorial boards and has received numerous

awards.

This speaker also appears in:

Dr. Yilai Shu is a physician-scientist in the department of otolaryngology at Eye & ENT Hospital of Fudan University. He obtained both an M.D. and Ph.D. degree in otolaryngology. From 2010 to 2014, he studied as a PhD student in the joint training program and continued his research as a postdoctoral fellow at Massachusetts Eye and Ear-Harvard Medical School. Now, he serves as the vice president of Eye & ENT Hospital of Fudan University and Director of the Diagnosis and Treatment Center for Hereditary Deafness. His clinical interests are Otology and Neurotology. He is an expert in gene therapy and translational medicine of hereditary deafness based on gene replacement or CRISPR/Cas9 gene editing, hair cell regeneration in the inner ear, and hearing protection. He has developed a gene therapy candidate drug—AAV-hOTOF—for the treatment of hearing loss caused by genetic defects and successfully spearheaded the world’s first clinical trial in this groundbreaking field. He was awarded the 2025 ARO Award for Clinical Innovation and the XPLORER PRIZE for his commitment to advancing gene therapy treatments for hearing restoration.

This speaker also appears in: